Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Boca Raton, Huntington Beach, Kansas City, New York, Park Ridge, and Philadelphia, United StatesSee the 7 sitesAlso in 10 other countries, 20 sites
- Trial code
- NCT05130450
- EU 2023-509029-29-00
- EudraCT 2021-003280-95
- U1111-1299-3265
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 60 people enrolled
- Started
- 18 Nov 2021
- Expected to end
- Feb 2028
- Type of study
- Interventional
- Treatments tested
- Olezarsen
- Record updated
- 12 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Satisfactory completion of treatment with olezarsen in the index study (ISIS 678354-CS3, last dose as scheduled at Week 49) with an acceptable safety profile, per Investigator judgement
Who cannot take part
- Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the patient participating in or completing the study, including need for treatment with medications disallowed in the index study (ISIS 678354-CS3)
Where in United States
Also in 10 other countries, 20 sites
- Excel Medical Clinical Trials, LLCBoca Raton, United States
- Diabetes/Lipid Management & Research CenterHuntington Beach, United States
- University of Kansas Medical Center (KUMC)Kansas City, United States
- CTSI Investigational PharmacyNew York, United States
- Milstein HospitalNew York, United States
- Department of PharmacyPark Ridge, United States
- IDS CentralPhiladelphia, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.
The group in the trial
- OlezarsenTreatment being tested
Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 153.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
- Record updated
- 12 December 2025